10-Q: Atossa Therapeutics Faces Going Concern Doubt Amidst Clinical Progress

Atossa Therapeutics reported continued net losses and substantial doubt regarding its ability to continue as a going concern, despite advancements in its (Z)-endoxifen clinical trials and a recent capital raise.

Summary

• Atossa Therapeutics, Inc. filed its quarterly report for the period ended June 30, 2026.
• The company reported a net loss of $8.5 million for the three months ended June 30, 2026, and $18.1 million for the six months ended June 30, 2026.
• As of June 30, 2026, the company had $26.1 million in cash and cash equivalents, but substantial doubt exists regarding its ability to continue as a going concern.
• The company raised $4.0 million in net proceeds from a registered direct offering in June 2026 and $21 thousand from an at-the-market offering in the same period.
• Progress was noted in several clinical trials for (Z)-endoxifen, including Karisma, I-SPY 2, RECAST, and EVANGELINE, with some showing promising early results.
• The company received FDA designations for (Z)-endoxifen for Duchenne muscular dystrophy (DMD) and McCune-Albright Syndrome (MAS), including Rare Pediatric Disease and Orphan Drug designations.
• Operating expenses for the six months ended June 30, 2026, were $18.6 million, an increase from $16.5 million in the prior year period, primarily due to increased professional fees related to patent litigation.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the continued significant net losses, substantial doubt about the company's ability to continue as a going concern, and the need for substantial future capital raises, despite progress in clinical trials.

Positives

• The Karisma study showed significant reductions in mammographic breast density (MBD) with (Z)-endoxifen, with the 1 mg dose showing a 17.3% reduction and the 2 mg dose showing a 23.5% reduction.
• The I-SPY 2 study demonstrated biological activity for (Z)-endoxifen, including reductions in Ki-67 proliferation index and median MRI functional tumor volume reduction of approximately 72%.
• The EVANGELINE study completed enrollment as of June 30, 2026, with early pharmacodynamic data showing strong biologic activity.
• Atossa received FDA Rare Pediatric Disease designations for (Z)-endoxifen for DMD and MAS, and Orphan Drug designations for DMD.
• The company settled patent litigation with Intas Pharmaceuticals Ltd. and Jina Pharmaceuticals, Inc., leaving its key patents enforceable.
• The company successfully raised $4.0 million in net proceeds from a registered direct offering in June 2026.

Negatives

• The company incurred net losses of $8.5 million and $18.1 million for the three and six months ended June 30, 2026, respectively.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to its history of net losses and negative operating cash flows.
• The company expects its existing resources to be insufficient to fund planned operations for the next twelve months, requiring additional capital.
• Operating expenses increased by $2.1 million for the six months ended June 30, 2026, compared to the prior year, largely due to increased legal fees from patent litigation.
• The company's cash and cash equivalents decreased from $41.3 million at December 31, 2025, to $26.1 million at June 30, 2026.
• A liability of $1.1 million was recorded for potential Australian R&D tax rebate disqualification.

Risks

• The company has a history of operating losses and expects to continue incurring losses, raising substantial doubt about its ability to continue as a going concern.
• The company will need to raise substantial additional capital in the future to fund its operations and may be unable to do so on acceptable terms.
• Compounds and methods that appear promising in research and development may fail to reach later stages of development.
• The company may not obtain or maintain the regulatory approvals required to develop or commercialize its products.
• The company is dependent on third-party service providers for critical operational and clinical trial activities, and any failure or delay could harm its business.
• The trading price of the company's common stock has been and is likely to continue to be volatile.
• The company may not be able to protect its proprietary technology and intellectual property rights.
• Macroeconomic factors such as high interest rates, inflation, and geopolitical instability could adversely impact the company's business and its ability to raise capital.

Future Outlook

The company expects to incur ongoing operating losses for the foreseeable future as it continues to develop its therapeutic programs. Future funding requirements will depend on factors such as manufacturing costs, clinical trial expenses, intellectual property costs, and potential acquisitions. Substantial doubt exists about the company's ability to continue as a going concern, and additional capital resources will be needed to fund operations longer-term. The company does not anticipate generating revenue until its pharmaceutical programs are developed, receive regulatory approvals, and are successfully commercialized.

Management Comments

• Management maintains that in order to alleviate the conditions that raise substantial doubt, the Company will need, among other things, additional capital resources.
• Management plans to obtain such resources for the Company include obtaining capital from the sale of its equity securities as well as short-term borrowings from banks, stockholders or other related parties if needed.
• However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.

Industry Context

StockSavvy.ai notes that Atossa Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on oncology and rare diseases. The company's reliance on (Z)-endoxifen, a promising but still investigational drug, places it in a typical clinical-stage development pathway where significant R&D investment is required, and success is contingent on regulatory approvals and market adoption. The current macroeconomic environment, characterized by higher interest rates and inflation, exacerbates the challenges of securing necessary funding for such ventures.

Comparison to Industry Standards

• The company's net loss of $18.1 million for the first six months of 2026 is substantial for a clinical-stage biopharmaceutical company, but not uncommon given the high costs of drug development.
• The cash burn rate of $19.2 million for the first six months of 2026 is a critical metric. Companies in this sector often have cash runways of 12-18 months, and Atossa's current resources may be insufficient for the next twelve months, indicating a need for further fundraising.
• The successful settlement of patent litigation with Intas Pharmaceuticals and Jina Pharmaceuticals is a positive step, as patent disputes can be costly and time-consuming, impacting development timelines and market exclusivity for companies like Atossa and its competitors such as Pfizer (with its breast cancer treatments) or Novartis.
• The FDA's granting of Rare Pediatric Disease and Orphan Drug designations for (Z)-endoxifen for DMD and MAS aligns with industry trends of incentivizing development for rare and underserved conditions, similar to how companies like Sarepta Therapeutics have benefited from such designations for Duchenne-related therapies.

Legal Proceedings

• On April 3, 2025, Intas Pharmaceuticals Ltd. filed Petitions for Post Grant Review and Inter Partes Review seeking to invalidate two of the Company's issued patents related to Endoxifen.
• On April 13, 2026, the Company entered into a settlement agreement with Intas and Jina Pharmaceuticals, Inc., which fully resolved these petitions, and the PTAB proceedings were terminated.
• The Company's two issued patents (U.S. Patents Nos. 11,261,151 and 12,071,391) remain issued and fully enforceable against other third parties.
• The settlement includes mutual covenants not to challenge specified Endoxifen-related patents and patent applications.

Stakeholder Impact

• Shareholders may experience dilution due to ongoing capital raises through equity offerings.
• The company's ability to continue as a going concern poses a significant risk to shareholders' investment.
• Employees may face uncertainty due to the company's financial situation and the need for future capital.
• Creditors and suppliers may face risks if the company is unable to secure sufficient funding to meet its obligations.

Next Steps

• Expect to receive top-line durability data from the Karisma-(Z)-endoxifen study in the third quarter of 2026.
• Expect to begin receiving data from the expanded arms of the I-SPY 2 study using (Z)-endoxifen as combination therapy throughout the second half of 2026.
• Intend to pursue Orphan Drug designation for McCune-Albright Syndrome in the second half of 2026.
• Continue to advance (Z)-endoxifen programs through clinical studies.
• Opportunistically add programs in areas of high unmet medical need through acquisition, minority investment, collaboration or internal development.

Key Dates

Recommendation

The company continues to incur substantial net losses and faces significant doubt regarding its ability to continue as a going concern. While there is progress in clinical trials and FDA designations, the need for substantial future capital raises, coupled with the inherent risks of drug development and volatile stock performance, presents a high-risk investment profile. The current financial precariousness outweighs the potential future success of its drug candidates.

Keywords

Atossa Therapeutics, (Z)-endoxifen, breast cancer, clinical trials, oncology, biopharmaceutical, going concern, capital raise